Bacterial Strain Articles & Analysis: Older
23 news found
In this test, the MIC and MBC values of the test compounds are used individually and combined with the MIC and MBC values of each bacterial strain being evaluated to calculate accumulation. Synergy measurements by checkerboard analysis can be utilized to determine changes in the antibacterial potency of an antibiotic combination relative to its activity. ...
Plasmids are transmissible between host cells, leading to the rapid dissemination of their accessory genes through bacterial communities. The Food Safety Authority (EFSA or FDA) requires critical plasmid information for the food or feed industry, mainly because of the spread of antibiotic resistance traits. ...
The warrants shall entitle to subscription for a maximum of 304,500 B-shares in the company during the period June 1, 2025 up to and including September 30, 2025 at a subscription price corresponding to 200 percent of the volume-weighted average price of the company’s share according to Nasdaq Stockholm’s official price list during ten trading days before May 4, 2022. About Infant ...
The analyses cover several defined bacterial consortia candidates developed by Vedanta, and include assessments of safety, tolerability, efficacy, and the relationships between dosing regimen, consortium strain colonization, and restoration of a patient’s resident microbial community. ...
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. ...
VAXIMM’s plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target a wide range of cancer-related antigens. ...
These miracle drugs could be prescribed broadly by physicians to cure a plethora of ailments without identifying the specific pathogenic strain. In stark contrast, phage therapies required isolation of specific phages to treat each bacterial pathogen, specific diagnosis of the pathogen afflicting each patient, and a much more complex manufacturing process than ...
” Tweet this “To our knowledge, this is the first randomized clinical trial to demonstrate that a live bacterial product can modulate the gastrointestinal microbiome and enhance immunotherapy response in cancer patients. ...
The DMC is expected to give their opinion in September this year. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). Infant Bacterial Therapeutics AB (publ) (“IBT”) ...
Data from the study demonstrated that an LBP – Clostridium butyricum MIYAIRI 588® strain (CBM588) – plus nivolumab/ipilimumab improved overall response rate (ORR) and progression-free survival (PFS) compared to nivolumab/ipilimumab alone in patients with metastatic renal cell carcinoma (RCC). ...
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from ...
The data presented further supports development of CRISPR-Cas antimicrobial strategies against STEC and other microbiome bacterial targets utilizing Eligo’s proprietary Eligobiotics® platform. ...
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus ...
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. ...
It was also investigated whether there is a cross-reaction with other pathogenic bacterial strains such as E.coli, S. Typhi or L.innocua. The authors used Chitosan 85/1000 (deacetylation degree/viscosity) from Heppe Medical Chitosan GmbH for the membrane. ...
Products from Intus Biosciences demonstrated high-resolution tracking of specific bacterial strains in a recent microbiome study, the results of which are being applied to better understand how pathogens and commensals become established in premature infants in neonatal intensive care units (NICU), with the goal of improving outcomes for premature infants. ...
Osel is developing LACTIN-V, a proprietary formulation of Lactobacillus crispatus being studied in IVF, in addition to bacterial vaginosis (BV) and pre-term birth. Last year, Osel and colleagues published data in The New England Journal of Medicine demonstrating that LACTIN-V significantly reduced the recurrence of BV versus placebo in a Phase 2b trial. ...
Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced clinical data showing that the company’s LACTIN-V LBP significantly reduced the recurrence of bacterial vaginosis (BV) vs. placebo in a Phase 2b trial. Results were published in the New England Journal of Medicine: ...
ART24 is a naturally occurring, pure bacterial strain which was discovered by Artugen Therapeutics in collaboration with APC Microbiome Ireland. ...
“As we increasingly look to the gut microbiome to solve major health issues, it’s important that we identify the specific abilities of bacterial strains (i.e. probiotics) when using objective markers of clinical outcomes in studies which demonstrate the capacity of these bacteria to resolve well-defined clinical problems as a result of their ...